The announcement was welcome news for those with major depressive disorder, affecting an estimated 8.3% of the adult ...

An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration ...

Johnson & Johnson's Spravato nasal spray has been FDA-approved as a stand-alone therapy for adults with treatment-resistant ...

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at least two oral ...

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...

The U.S. Food and Drug Administration has approved a nasal spray that is known to help treat depression.

If you’ve been diagnosed with major depressive disorder or a form of anxiety, your mental health provider may prescribe the ...

The U.S. Food and Drug Administration ( FDA) has approved the use of a nasal spray as a standalone treatment for major depressive disorder, offering a new option for those struggling with ...

The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson's nasal spray, Spravato (esketamine), as the first ...

The FDA approved Johnson & Johnson’s Spravato nasal spray as a stand-alone treatment for patients suffering from severe ...